CGON
Price
$24.85
Change
+$0.50 (+2.05%)
Updated
Aug 8 closing price
Capitalization
1.89B
SYRE
Price
$15.24
Change
-$0.00 (-0.00%)
Updated
Aug 8 closing price
Capitalization
915.68M
89 days until earnings call
Interact to see
Advertisement

CGON vs SYRE

Header iconCGON vs SYRE Comparison
Open Charts CGON vs SYREBanner chart's image
CG Oncology
Price$24.85
Change+$0.50 (+2.05%)
Volume$672.66K
Capitalization1.89B
Spyre Therapeutics
Price$15.24
Change-$0.00 (-0.00%)
Volume$417.79K
Capitalization915.68M
CGON vs SYRE Comparison Chart in %
Loading...
CGON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGON vs. SYRE commentary
Aug 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGON is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 09, 2025
Stock price -- (CGON: $24.85 vs. SYRE: $15.16)
Brand notoriety: CGON and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGON: 79% vs. SYRE: 44%
Market capitalization -- CGON: $1.89B vs. SYRE: $915.68M
CGON [@Biotechnology] is valued at $1.89B. SYRE’s [@Biotechnology] market capitalization is $915.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGON’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • CGON’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, both CGON and SYRE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGON’s TA Score shows that 3 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • CGON’s TA Score: 3 bullish, 5 bearish.
  • SYRE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than CGON.

Price Growth

CGON (@Biotechnology) experienced а -5.55% price change this week, while SYRE (@Biotechnology) price change was -6.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.11%. For the same industry, the average monthly price growth was +5.28%, and the average quarterly price growth was +13.38%.

Reported Earning Dates

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CGON($1.89B) has a higher market cap than SYRE($916M). CGON YTD gains are higher at: -13.354 vs. SYRE (-34.880). CGON has higher annual earnings (EBITDA): -134.35M vs. SYRE (-214.36M). CGON has more cash in the bank: 688M vs. SYRE (565M). SYRE has less debt than CGON: SYRE (0) vs CGON (1.04M). CGON has higher revenues than SYRE: CGON (662K) vs SYRE (0).
CGONSYRECGON / SYRE
Capitalization1.89B916M207%
EBITDA-134.35M-214.36M63%
Gain YTD-13.354-34.88038%
P/E RatioN/A1.68-
Revenue662K0-
Total Cash688M565M122%
Total Debt1.04M0-
FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
63
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
83
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CGONSYRE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 11 days ago
75%
Bullish Trend 18 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
CGON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MVCKX32.400.09
+0.28%
MFS Mid Cap Value R6
FIEUX44.47N/A
N/A
Fidelity Europe
HRLSX9.38N/A
N/A
Hartford Real Asset R4
NWKAX15.26-0.04
-0.26%
Nationwide Geneva Mid Cap Gr R6
OPMSX30.03-0.16
-0.53%
Invesco Main Street Mid Cap A

CGON and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGON has been loosely correlated with IDYA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if CGON jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGON
1D Price
Change %
CGON100%
+2.05%
IDYA - CGON
60%
Loosely correlated
+3.08%
SYRE - CGON
60%
Loosely correlated
-0.52%
ACLX - CGON
56%
Loosely correlated
-0.91%
KYMR - CGON
56%
Loosely correlated
-0.56%
NUVL - CGON
55%
Loosely correlated
+2.70%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with IDYA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-0.52%
IDYA - SYRE
60%
Loosely correlated
+3.08%
CGON - SYRE
60%
Loosely correlated
+2.05%
BEAM - SYRE
59%
Loosely correlated
-1.34%
XNCR - SYRE
57%
Loosely correlated
-1.23%
CRNX - SYRE
55%
Loosely correlated
-3.69%
More